THTX vs. PRLD, OVID, EPIX, DSGN, RZLT, VTYX, RANI, TSVT, ZVRA, and ME
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Prelude Therapeutics (PRLD), Ovid Therapeutics (OVID), ESSA Pharma (EPIX), Design Therapeutics (DSGN), Rezolute (RZLT), Ventyx Biosciences (VTYX), Rani Therapeutics (RANI), 2seventy bio (TSVT), Zevra Therapeutics (ZVRA), and 23andMe (ME). These companies are all part of the "pharmaceutical preparations" industry.
Prelude Therapeutics (NASDAQ:PRLD) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.
Prelude Therapeutics has a net margin of 0.00% compared to Prelude Therapeutics' net margin of -23.04%. Prelude Therapeutics' return on equity of 0.00% beat Theratechnologies' return on equity.
Prelude Therapeutics currently has a consensus price target of $5.25, suggesting a potential upside of 34.62%. Given Theratechnologies' higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than Theratechnologies.
In the previous week, Theratechnologies had 3 more articles in the media than Prelude Therapeutics. MarketBeat recorded 4 mentions for Theratechnologies and 1 mentions for Prelude Therapeutics. Theratechnologies' average media sentiment score of 1.89 beat Prelude Therapeutics' score of 1.31 indicating that Prelude Therapeutics is being referred to more favorably in the media.
79.7% of Prelude Therapeutics shares are owned by institutional investors. 62.8% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Theratechnologies received 4 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 52.73% of users gave Theratechnologies an outperform vote while only 48.08% of users gave Prelude Therapeutics an outperform vote.
Prelude Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.
Theratechnologies has higher revenue and earnings than Prelude Therapeutics. Theratechnologies is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Theratechnologies beats Prelude Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theratechnologies Competitors List
Related Companies and Tools
